1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends

Physician Views: Key developments in the European diabetes market - will endocrinologists embrace Tresiba and Forxiga? – both rejected by the FDA

  • July 2013
  • Firstword Pharma
Report ID: 1590711

Summary

Table of Contents

Scope of the Report

European-based endocrinologists are currently getting to grips with two new products that have been rejected for approval in the US market. Novo Nordisk’s long-acting basal insulin Tresiba – a potential competitor to Sanofi’s market leading Lantus franchise – and AstraZeneca and Bristol-Myers Squibb’s SGLT-2 inhibitor Forxiga.

Assessing how European physicians perceive these products is important. In the case of Tresiba, analysts are bullish that Novo Nordisk’s franchise can still generate blockbuster revenues based on its performance in ex-US markets, the key implication (from a commercial perspective) being how this will impact sales of Sanofi’s Lantus, the potential launch of its follow-up product Lantus U300 and Eli Lilly’s own investments in the long-acting basal insulin market. See ViewPoints: Sanofi's 'mega brand' Lantus the key beneficiary of Novo Nordisk's degludec setback.

In the case of Forxiga, AstraZeneca and Bristol-Myers Squibb are expected to resubmit the drug to the FDA later this year. Another SGLT-2 inhibitor – Johnson & Johnson’s Invokana – has launched in the US market and performed more robustly than analysts had anticipated - see ViewPoints: Have analysts undervalued the SGLT-2 diabetes drug class? and Physician Views poll results: Endocrinologists increasingly less concerned about DPP-4/GLP-1 safety risk/Impressed with Johnson & Johnson's Invokana.

Early perception towards Forxiga is thus important on two fronts; can AstraZeneca and Bristol-Myers Squibb’s product emerge as a key player in the European SGLT-2 market (and potentially in the US market) and is there any indication that the SGLT-2 market in Europe can develop similarly to the US; where Invokana has been submitted to the European Medicines Agency but has yet to be approved.

Reasons to Buy this Report

This week's Physician Views poll will specifically ask endocrinologists based in the 5EU countries:

• To what percentage of eligible patients they anticipate prescribing Tresiba to in a year’s time?
• Whether the FDA’s decision not to approve Tresiba (pending data from a cardiovascular outcomes study) will have any impact on your own prescribing of the product?
• How endocrinologists describe their initial usage of Forxiga
• To what percentage of total diabetes patients they expect to be prescribing SGLT-2 inhibitors to in two years time?
• Based on usage to date where they believe the most likely to use SGLT-2 inhibitors within the treatment paradigm?



Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

Ahmad helps you find the right report:

Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

Purchase Reports From Reputable Market Research Publishers

Empagliflozin Sales, Price Analysis, & Sales Forecast - 2017

  • $ 1100
  • Industry report
  • April 2017
  • by Fore Pharma

Fore Pharma has released its new research, Empagliflozin Sales, Price Analysis, & Sales Forecast – 2017. Find out the sales of Empagliflozin worldwide and by countries in North America, Europe, Japan, ...

Dapagliflozin Sales, Price Analysis, & Sales Forecast - 2017

  • $ 1100
  • Industry report
  • April 2017
  • by Fore Pharma

Fore Pharma has released its new research, Dapagliflozin Sales, Price Analysis, & Sales Forecast – 2017. Find out the sales of Dapagliflozin worldwide and by countries in North America, Europe, Japan, ...

Dapagliflozin / Metformin Sales, Price Analysis, & Sales Forecast - 2017

  • $ 1100
  • Industry report
  • April 2017
  • by Fore Pharma

Fore Pharma has released its new research, Dapagliflozin / Metformin Sales, Price Analysis, & Sales Forecast – 2017. Find out the sales of Dapagliflozin / Metformin worldwide and by countries in North ...


ref:plp2013

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.